Breaking News Instant updates and real-time market news.

NKTR

Nektar

$101.44

-0.41 (-0.40%)

13:05
04/06/18
04/06
13:05
04/06/18
13:05

Nektar call volume above normal and directionally bullish

Bullish option flow detected in Nektar with 3,289 calls trading, 4x expected, and implied vol increasing over 5 points to 74.81%. May-18 110 calls and Apr-18 90 puts are the most active options, with total volume in those strikes near 2,800 contracts. The Put/Call Ratio is 0.43. Earnings are expected on May 9th.

  • 14

    Apr

  • 03

    May

  • 12

    Jun

NKTR Nektar
$101.44

-0.41 (-0.40%)

03/02/18
JPMS
03/02/18
NO CHANGE
Target $90
JPMS
Overweight
Nektar announced another positive update on NKTR-214, says JPMorgan
Nektar Therapeutics last night announced another positive update on NKTR-214 from the phase I dose escalation study and reported additional patients converted to responders, JPMorgan analyst Jessica Fye tells investors in a post-earnings research note. The analyst continues to see NKTR-214, along with the company's immunology/immuno-oncology pipeline, driving potential "significant value creation." She keeps an Overweight rating on Nektar with a $90 price target.
03/02/18
MZHO
03/02/18
NO CHANGE
Target $89
MZHO
Buy
Mizuho has increased conviction in Bristol possibly buying Nektar in 2018
Mizuho analyst Difei Yang believes there is a possibility for Bristol-Myers Squibb (BMY) to acquire Nektar Therapeutics (NKTR) in 2018. The analyst says new positive clinical data of NKTR-214 in combo with Bristol-Myers' Opdivo reinforces her conviction. Bristol-Myers "could make a move" prior to the readouts of Propel study, expected in the second half of 2018, where NKTR-214 was tested in combo with competing products, Tecentiq and Keytruda, Yang tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $89 price target following the company's Q4 results.
03/02/18
ADAM
03/02/18
NO CHANGE
Target $94
ADAM
Buy
Nektar price target raised to $94 from $80 at Canaccord
Canaccord Genuity analyst Arlinda Lee raised her price target for Nektar Therapeutics to $94 after the company reported Q4 results. Notable, Nektar provided a second update to Phase 1 Pivot-2 dose-escalation results indicating ongoing and further tumor shrinkage with improved and continuing response, Lee tells investors in a research note. Further, the company reported 60% response rate in 20 patients with PDL1-negative tumors at baseline, the analyst adds. She believes the update "further solidifies the central positioning" for wholly-owned drug candidate NKTR-214 in combination with anti-PD1. The analyst keeps a Buy rating on Nektar.
04/02/18
HCWC
04/02/18
INITIATION
Target $125
HCWC
Buy
Nektar assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay assumed coverage of Nektar Therapeutics with a Buy rating and $125 price target. The stock has had a "stellar run, but activity in checkpoint refractory patients could be well received," Chattopadhyay tells investors in a research note. The analyst believes available data from NKTR-214 in combination with Opdivo points to "compelling clinical activity." He sees "significant upside to the stock" beyond what his $125 target suggests should the data hold up to scrutiny.

TODAY'S FREE FLY STORIES

LIND

Lindblad Expeditions

$15.18

-0.12 (-0.78%)

05:55
03/22/19
03/22
05:55
03/22/19
05:55
Conference/Events
Lindblad Expeditions management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

DRI

Darden

$116.11

7.485 (6.89%)

05:53
03/22/19
03/22
05:53
03/22/19
05:53
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMC

Commercial Metals

$17.35

1.29 (8.03%)

05:43
03/22/19
03/22
05:43
03/22/19
05:43
Upgrade
Commercial Metals rating change  »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$134.59

2.69 (2.04%)

05:42
03/22/19
03/22
05:42
03/22/19
05:42
Upgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

  • 24

    Apr

BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:42
03/22/19
03/22
05:42
03/22/19
05:42
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

BBY

Best Buy

$70.56

1.44 (2.08%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Upgrade
Best Buy rating change  »

Best Buy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAR

Varian Medical

$137.77

1.97 (1.45%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Upgrade
Varian Medical rating change  »

Varian Medical upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Downgrade
Biogen rating change  »

Citi downgrades Biogen to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

FTI

TechnipFMC

$23.83

0.09 (0.38%)

05:40
03/22/19
03/22
05:40
03/22/19
05:40
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

RYB

RYB Education

$8.01

0.09 (1.14%)

05:40
03/22/19
03/22
05:40
03/22/19
05:40
Downgrade
RYB Education rating change  »

RYB Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOV

Spark Networks

$11.29

(0.00%)

05:26
03/22/19
03/22
05:26
03/22/19
05:26
Conference/Events
Spark Networks to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

ESALY

Eisai

$0.00

(0.00%)

05:25
03/22/19
03/22
05:25
03/22/19
05:25
Downgrade
Eisai rating change  »

Eisai downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$0.00

(0.00%)

, BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:24
03/22/19
03/22
05:24
03/22/19
05:24
Hot Stocks
Eisai announces initiation of Phase III BAN2401 study in Alzheimer's disease »

Eisai (ESALY) announced…

ESALY

Eisai

$0.00

(0.00%)

BIIB

Biogen

$226.71

-93.76 (-29.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

ZUO

Zuora

$24.34

0.62 (2.61%)

05:18
03/22/19
03/22
05:18
03/22/19
05:18
Recommendations
Zuora analyst commentary at Jefferies »

Zuora business metrics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

OPHRY

Ophir Energy

$0.00

(0.00%)

05:15
03/22/19
03/22
05:15
03/22/19
05:15
Downgrade
Ophir Energy rating change  »

Ophir Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELNY

Telenor

$0.00

(0.00%)

05:13
03/22/19
03/22
05:13
03/22/19
05:13
Downgrade
Telenor rating change  »

Telenor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KGFHY

Kingfisher

$0.00

(0.00%)

05:13
03/22/19
03/22
05:13
03/22/19
05:13
Downgrade
Kingfisher rating change  »

Kingfisher downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$31.29

0.78 (2.56%)

05:11
03/22/19
03/22
05:11
03/22/19
05:11
Earnings
Health Insurance confirms 2019 outlook, calls shares 'compelling value' »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

HIIQ

Health Insurance Innovations

$31.29

0.78 (2.56%)

05:07
03/22/19
03/22
05:07
03/22/19
05:07
Hot Stocks
Health Insurance CEO says multi-state regulatory review found no issues »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

PSO

Pearson

$10.96

0.07 (0.64%)

05:02
03/22/19
03/22
05:02
03/22/19
05:02
Upgrade
Pearson rating change  »

Pearson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$52.05

2.395 (4.82%)

04:59
03/22/19
03/22
04:59
03/22/19
04:59
Upgrade
Lumentum rating change at JPMorgan »

Lumentum upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

PPG

PPG

$112.60

1.73 (1.56%)

04:58
03/22/19
03/22
04:58
03/22/19
04:58
Downgrade
PPG rating change at JPMorgan »

PPG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

SHW

Sherwin-Williams

$433.70

4.385 (1.02%)

04:57
03/22/19
03/22
04:57
03/22/19
04:57
Downgrade
Sherwin-Williams rating change at JPMorgan »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

MDB

MongoDB

$154.52

10.73 (7.46%)

04:55
03/22/19
03/22
04:55
03/22/19
04:55
Initiation
MongoDB initiated at William Blair »

MongoDB initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
03/22/19
03/22
04:55
03/22/19
04:55
General news
Breaking General news story  »

Week of 3/22 Baker-Hughes…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.